Evaluating the efficacy of risperidone in the treatment of ADHD

Comparison of the Effectiveness of Risperidone and Standard Treatment in Reducing Symptoms of Children with Attention-Deficit/Hyperactivity Disorder (ADHD)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241228064189N1

Enrollment

Registered

2025-10-16

Start date

2025-09-23

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

children diagnosed with ADHD. Attention-deficit hyperactivity disorder, predominantly inattentive type

Interventions

Intervention Group 1:Assessment of ADHD severity in children aged 3 to 12 years diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) based on the evaluation of a pediatric neurology subspeci

Eligibility

Sex/Gender

All

Age

3 Years to 12 Years

Inclusion criteria

Inclusion criteria: All children aged 3-12 with a diagnosis of ADHD (according to the opinion of a pediatric neurologist) No history of risperidone use

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Score of ADHD symptoms from the parents’ perspective before receiving risperidone in children diagnosed with ADHD. Timepoint: Score of ADHD symptom Before the intervention (baseline), the first month, the second month, and the third month. Method of measurement: Conners reviesed rating scale & ADHD rating scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRana Eskandari

Oroumia University of Medical Sciences

eskandari.r@umsu.ac.ir+98 44 3428 3025

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026